Mon, 18 Oct 2021 12:00:00 EDT Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients Conditions: Interaction, Adverse Herb-Drug; Diabetes Mellitus, Type 2 Interventions: Drug: Midazolam Hcl 1Mg/Ml Inj; Dietary Supplement: Goldenseal (Hydrastis canadensis) Sponsors: Washington State University; National Center for Complementary and Integrative Health (NCCIH) Recruiting
Mon, 18 Oct 2021 12:00:00 EDT De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease Conditions: Stable Ischemic Heart Disease; Coronary Artery Disease; Beta-blocker Therapy Interventions: Other: Medical Assessment; Other: Quality of Life Assessment Sponsor: University of Alberta Not yet recruiting
Mon, 18 Oct 2021 12:00:00 EDT Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS) Conditions: Gestational Diabetes; Glucose Metabolism Disorders; Metabolic Disease Intervention: Device: Wearable Care Group Sponsors: KK Women's and Children's Hospital; Duke-NUS Graduate Medical School; Singapore Institute for Clinical Sciences Recruiting
Mon, 18 Oct 2021 12:00:00 EDT Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging Condition: Coronary Artery Disease;Heart Failure;Hypertrophic Cardiomyopathy; Congenital and Valvular Heart Disease; Post-chest Radio/Chemiotherapy; Heart Transplantation Interventions: Diagnostic Test: ABCDE-Stress Echo; Diagnostic Test: SE diastolic assessment; Diagnostic Test: SE Right ventricular function assessment; Diagnostic Test: SE in heart donors Sponsors: Fatebenefratelli Hospital; Institute oif Clinical Physiology,CNR, Pisa Italy; Mayo Clinic; Hospital Sao Vicente de Paulo e Hospital de Cidade, Passo Fundo, Brasil; Cardarelli Hospital, Naples, Italy; Ospedale per gli Infermi, Faenza, Ravenna, Italy; Institute of Family Medicine, University of Szeged, Hungary; Montepulciano Hospital, Siena; University of Pisa, Italy; University Hospital, Pleven, Bulgaria; Tomsk National Research Medical Centre of the Russian; University Hospital, Szeged, Hungary; Elisabeth Hospital, Hódmezővásárhely, Hungary; DASA, San Paolo, Brasil; University of Banja Luka University Clinical Centre of the Republic of Srpska; University of A Coruna, La Coruna, Spain; Antwerp University Hospital, Edegem, Belgium; Università Luigi Vanvitelli della Campania; Dolo Hospital, Venice, Italy; Institute for Cardiovascular Diseases Dedinje, School of Medicine, Belgrade, Serbia; Investigaciones Medicas, Buenos Aires, Argentina; Bieganski Hospital, Medical University, Lodz, Poland; Medical University of Silesia, Katowice, Poland; Federal University of Paranà, Curitiba, Brasil; Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Careggi Hospital, Florence; Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico; Saint Petersburg State University Hospital, Russian Federation; Clinical Hospital Zvezdara, Medical School, University of Belgrade, Serbia; University Center Serbia, Medical School, University of Belgrade, Serbia; University Hospital, Padua, Italy; Sant'Anna School of Advanced Study, Pisa; University Hospital, Siena, Italy; Vilnius University, Lithuania; University of Parma; University of Verona, Italy; Malpighi Hospital, Bologna, Italy; University of Modena and Reggio Emilia, Italy; Presidio Ospedale San Paolo. Milano; IRCCS Reggio Emilia, Italy.; Association for Public Health "Salute Pubblica", Brindisi, Italy; Catania University, Italy; Ospedale San Camillo, Rome, Italy; University of Salerno, Italy; University of Algarve, Portugal.; Heart Center, Hospital da Cruz Vermelha, Lisbon; University of Bari; Hospital Motta di Livenza, Treviso, Italy; Centro Cardiologico Monzino; Italian Society of Echocardiography and Cardiovascular Imaging; San Luca Hospital, Lucca, Italy; Hospital Sao José, Criciuma Recruiting
Mon, 18 Oct 2021 12:00:00 EDT The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib Condition: Ovary Cancer Interventions: Drug: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.); Device: Lynparza Sponsors: Poznan University of Medical Sciences; Poznan University Hospital of Lord's Transfiguration Recruiting
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Latest Top (10) News
FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira The U.S. Food and Drug Administration today approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm) is now approved as interchangeable with (and may be substituted for) its reference product Humira (adalimumab).
